A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Clear Cell Renal Cell Carcinoma
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Neuroendocrine Tumors
MSI-H Cancer
Cancer With A High Tumor Mutational Burden
Extensive-stage Small-cell Lung Cancer

Interventions

DRUG: 23ME-00610

Sponsor

23andMe, Inc.